BCIQ Profiles

Company Profile Report

Axicabtagene ciloleucel: Updated Ph I/II ZUMA-1 data

Updated data from 101 patients with chemorefractory aggressive B cell NHL in the modified intent-to-treat (mITT) population of the open-label, U.S. and Israeli Phase I/II ZUMA-1 trial showed that a single IV

Read the full 323 word article

How to gain access

Continue reading with a
two-week free trial.